Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on April 27, 2009

Hypertension. 2009
Published online before print April 27, 2009, doi: 10.1161/HYPERTENSIONAHA.108.123158
A more recent version of this article appeared on June 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
53/6/1041    most recent
HYPERTENSIONAHA.108.123158v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levick, S. P.
Right arrow Articles by Brower, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levick, S. P.
Right arrow Articles by Brower, G. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Structure
Right arrow Remodeling
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease

Submitted on September 15, 2008
Revised on October 23, 2008

Cardiac Mast Cells Mediate Left Ventricular Fibrosis in the Hypertensive Rat Heart

Scott P. Levick; Jennifer L. McLarty; David B. Murray; Rebecca M. Freeman; Wayne E. Carver; and Gregory L. Brower*

From the Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia.

* To whom correspondence should be addressed. E-mail: Gregory.Brower{at}uscmed.sc.edu.

Abstract—Correlative data suggest that cardiac mast cells are a component of the inflammatory response that is important to hypertension-induced adverse myocardial remodeling. However, a causal relationship has not been established. We hypothesized that adverse myocardial remodeling would be inhibited by preventing the release of mast cell products that may interact with fibroblasts and other inflammatory cells. Eight-week-old male spontaneously hypertensive rats were treated for 12 weeks with the mast cell stabilizing compound nedocromil (30 mg/kg per day). Age-matched Wistar-Kyoto rats served as controls. Nedocromil prevented left ventricular fibrosis in the spontaneously hypertensive rat independent of hypertrophy and blood pressure, despite cardiac mast cell density being elevated. The mast cell protease tryptase was elevated in the spontaneously hypertensive rat myocardium and was normalized by nedocromil. Treatment of isolated adult spontaneously hypertensive rat cardiac fibroblasts with tryptase induced collagen synthesis and proliferation, suggesting this as a possible mechanism of mast cell–mediated fibrosis. In addition, nedocromil prevented macrophage infiltration into the ventricle. The inflammatory cytokines interferon-{gamma} and interleukin (IL)-4 were increased in the spontaneously hypertensive rat and normalized by nedocromil, whereas IL-6 and IL-10 were decreased in the spontaneously hypertensive rat, with nedocromil treatment normalizing IL-6 and increasing IL-10 above the control. These results demonstrate for the first time a causal relationship between mast cell activation and fibrosis in the hypertensive heart. Furthermore, these results identify several mechanisms, including tryptase, inflammatory cell recruitment, and cytokine regulation, by which mast cells may mediate hypertension-induced left ventricular fibrosis.


Key words: hypertension • collagen • cytokines • inflammation